Moors & Cabot Inc. Has $35,000 Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

Moors & Cabot Inc. grew its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 84.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,000 shares of the medical instruments supplier’s stock after buying an additional 16,000 shares during the period. Moors & Cabot Inc.’s holdings in OraSure Technologies were worth $35,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in OSUR. Lazard Asset Management LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at approximately $48,000. Parisi Gray Wealth Management acquired a new stake in shares of OraSure Technologies in the second quarter valued at approximately $68,000. Cresset Asset Management LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at approximately $110,000. PEAK6 Investments LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at approximately $117,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at approximately $119,000. 92.74% of the stock is owned by institutional investors.

NASDAQ:OSUR opened at $8.51 on Friday. The stock has a market cap of $613.04 million, a P/E ratio of -56.73 and a beta of -0.36. The stock has a 50 day simple moving average of $9.08 and a 200 day simple moving average of $10.27. The company has a current ratio of 5.34, a quick ratio of 4.35 and a debt-to-equity ratio of 0.01. OraSure Technologies, Inc. has a 1-year low of $7.56 and a 1-year high of $15.94.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, November 3rd. The medical instruments supplier reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). OraSure Technologies had a negative return on equity of 2.70% and a negative net margin of 4.61%. The company had revenue of $53.92 million for the quarter, compared to the consensus estimate of $47.54 million. During the same quarter last year, the business earned $0.01 EPS. As a group, sell-side analysts forecast that OraSure Technologies, Inc. will post -0.34 EPS for the current year.

A number of research firms have recently issued reports on OSUR. Zacks Investment Research cut OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday. Lake Street Capital dropped their price target on OraSure Technologies from $20.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, January 6th. Finally, Raymond James cut OraSure Technologies from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 22nd.

About OraSure Technologies

OraSure Technologies, Inc engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices.

See Also: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.